Question 1

What is Relmada Therapeutics's P/E ratio?

Accepted Answer

Relmada Therapeutics (RLMD) P/E ratio is currently not available. When trailing twelve-month earnings are negative (a net loss), the P/E ratio is mathematically meaningless and is reported as not available (N/A). In that case investors typically use P/S, EV/Sales, or forward P/E instead.

Question 2

How is the P/E ratio calculated?

Accepted Answer

P/E = Share Price ÷ Trailing Twelve-Month (TTM) Diluted EPS, or equivalently Market Capitalisation ÷ TTM Net Income. All inputs are sourced from audited GAAP/IFRS filings and translated to USD using period-end exchange rates so the multiple is comparable across companies and currencies.

Question 3

What is the P/E ratio?

Accepted Answer

The price-to-earnings (P/E) ratio, also called the earnings multiple, measures how much investors pay per dollar of a company's trailing twelve-month (TTM) earnings. It is calculated as share price ÷ TTM diluted EPS (equivalent to market capitalisation ÷ TTM net income). A higher P/E implies the market is pricing in stronger future earnings growth or lower risk; a lower P/E can signal slower expected growth, higher risk, or potential undervaluation.

Question 4

What is a good P/E ratio for Relmada Therapeutics?

Accepted Answer

There is no universal "good" P/E. As a rule of thumb, the S&P 500 has historically averaged a P/E in the mid-to-high teens; mature, slow-growth businesses commonly trade in the 10–18× range, while high-growth or asset-light companies often trade at 25–50×+. What matters is the comparison to sector peers and to the company's own historical range. For Relmada Therapeutics specifically, the relevant sector benchmark is the current sector median of 25.0×.

Question 5

What is Relmada Therapeutics's historical P/E ratio range?

Accepted Answer

In the available daily series, Relmada Therapeutics (RLMD) P/E ratio has ranged from a low of 0.6× in 2016 to a high of 1.0× in 2015.

Question 6

What was Relmada Therapeutics's P/E ratio in 2015?

Accepted Answer

Relmada Therapeutics (RLMD) P/E ratio at the end of 2015 was 1.0×. Annual values reflect the multiple on the last trading day of each calendar year, using the trailing twelve-month earnings figure available at that date.

Question 7

Why does Relmada Therapeutics's P/E ratio change over time?

Accepted Answer

Valuation multiples move with two inputs: the numerator (market capitalisation, which tracks the share price) and the denominator (earnings). Share-price changes — driven by interest rates, earnings expectations, risk appetite, and broader market sentiment — typically dominate short-term moves, while changes in the underlying fundamental drive the longer-term trend. As a result, the ratio can rise during stock-price rallies even if the business itself has not become more valuable, and fall during sell-offs even when fundamentals are improving.

Question 8

Why is Relmada Therapeutics's P/E ratio not available?

Accepted Answer

When trailing twelve-month earnings are negative (a net loss), the P/E ratio is mathematically meaningless and is reported as not available (N/A). In that case investors typically use P/S, EV/Sales, or forward P/E instead.


2025	$329.67M	−$57.39M	—	—	Dec 31, 2025
2024	$15.69M	−$79.98M	—	—	Dec 31, 2024
2023	$31.00M	−$98.79M	—	—	Dec 31, 2023
2022	$26.26M	−$157.04M	—	—	Dec 31, 2022
2021	$86.06M	−$125.75M	—	—	Dec 31, 2021
2020	$104.25M	−$59.46M	—	—	Dec 31, 2020
2019	$88.68M	−$15.01M	—	—	Dec 31, 2019
2018	$5.88M	−$17.06M	—	—	Dec 31, 2018
2017	$1.88M	−$6.02M	—	—	Dec 31, 2017
2016	$2.62M	−$7.85M	—	—	Dec 31, 2016
2015	$5.71M	$5.78M	1.0×	—	Dec 31, 2015
2014	$31.47M	−$52.22M	—	—	Dec 31, 2014
2013	$17.10M	−$50.37K	—	—	Nov 30, 2013
2012	$17.10M	−$20.63K	—	—	Nov 30, 2012


Medtronic (MDT)	22.2×
McKesson (MCK)	22.2×
Illumina (ILMN)	21.7×
ResMed (RMD)	21.6×
GE HealthCare (GEHC)	21.6×
Pfizer (PFE)	21.1×
Quest Diagnostics (DGX)	21.1×
Henry Schein (HSIC)	21.0×
AptarGroup (ATR)	20.9×
IQVIA (IQV)	20.7×
UnitedHealth Group (UNH)	20.4×
Biogen (BIIB)	19.7×
Zoetis (ZTS)	18.9×
Gilead Sciences (GILD)	18.8×
Humana (HUM)	18.5×
Regeneron Pharmaceuticals (REGN)	18.2×
Bristol-Myers Squibb (BMY)	17.0×
HCA Healthcare (HCA)	15.8×
DaVita (DVA)	13.3×
Incyte (INCY)	13.1×
Elevance Health (ELV)	12.3×
Cigna (CI)	11.1×
Novo Nordisk (NVO)	8.6×
Solventum (SOLV)	7.9×
Universal Health Services (UHS)	7.2×

P/E Ratio for Relmada Therapeutics (RLMD)

P/E Ratio daily chart for Relmada Therapeutics (RLMD)

Historical P/E Ratio for Relmada Therapeutics (RLMD) from 2012 to 2025

About P/E Ratio at Relmada Therapeutics (RLMD)

Relmada Therapeutics P/E Ratio by Year

Relmada Therapeutics P/E Ratio 2015: 1.0×

Sector peers by P/E Ratio — chart

Sector peers by P/E Ratio — table

Frequently asked questions

Relmada Therapeutics (RLMD) Key Financials

P/E Ratio daily chart for Relmada Therapeutics (RLMD)

Historical P/E Ratio for Relmada Therapeutics (RLMD) from 2012 to 2025

About P/E Ratio at Relmada Therapeutics (RLMD)

Relmada Therapeutics P/E Ratio by Year

Relmada Therapeutics P/E Ratio 2015: 1.0×

Sector peers by P/E Ratio — chart

Sector peers by P/E Ratio — table

Frequently asked questions

+What is Relmada Therapeutics's P/E ratio?

+How is the P/E ratio calculated?

+What is the P/E ratio?

+What is a good P/E ratio for Relmada Therapeutics?

+What is Relmada Therapeutics's historical P/E ratio range?

+What was Relmada Therapeutics's P/E ratio in 2015?

+Why does Relmada Therapeutics's P/E ratio change over time?

+Why is Relmada Therapeutics's P/E ratio not available?

Relmada Therapeutics (RLMD) Key Financials